AstraZeneca has received approval from the US Food and Drug Administration (FDA) for its Bruton’s tyrosine kinase ... binds covalently to the BTK active site to inhibit enzymatic activity ...

Now, Honigberg and colleagues describe an orally available, potent and selective inhibitor of the B-cell receptor (BCR) signalling molecule Bruton's tyrosine ... in the active site of BTK, was ...

Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology ...

Panelists discuss how data from Mansour and colleagues suggesting potential Bruton tyrosine kinase (BTK) inhibitor discontinuation after 2+ years of therapy opens up new treatment strategy ...